### PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY REC'D 0 6 JAN 2005 BRUCE E. PEACOCK WEGMAN, HESSLER & VANDERBURG 6055 ROCKSIDE WOODS BOULEVARD WRITTEN OPINION OF THE SUITE 200 INTERNATIONAL SEARCHING AUTHORITY CLEVELAND, OH 44131 (PCT Rule 43bis.1) Date of mailing JAN 2005 (day/month/year) FOR FURTHER ACTION Applicant's or agent's file reference See paragraph 2 below 020354079P2P Priority date (day/month/year) International filing date (day/month/year) International application No. 13 February 2004 (13.02.2004) 24 September 2004 (24.09.2004) PCT/US04/31365 International Patent Classification (IPC) or both national classification and IPC IPC(7): C02F 5/14 and US C1.: 210/699 Applicant GENERAL ELECTRIC COMPANY 1. This opinion contains indications relating to the following items: Basis of the opinion Box No. I Box No. II **Priority** Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Lack of unity of invention Box No. IV Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Certain documents cited Box No. VI Certain defects in the international application Box No. VII Certain observations on the international application Box No. VIII 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. 3. For further details, see notes to Form PCT/ISA/220. Authorized officer Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Peter A. Hruskoci Commissioner for Patents

Telephone No. 571-272-0987 Paralegal Sp

Facsimile No. (703) 305-3230
Form PCT/ISA/237 (cover sheet) (January 2004)

Alexandria, Virginia 22313-1450

P.O. Box 1450

International application No.

PCT/US04/31365

•
<ol> <li>With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.</li> </ol>
This opinion has been established on the basis of a translation from the original language into the following language which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
a. type of material
a sequence listing
table(s) related to the sequence listing
b. format of material
in written format
in computer readable form
c. time of filing/furnishing
contained in international application as filed.
filed together with the international application in computer readable form.
furnished subsequently to this Authority for the purposes of search.
Turmshed subsequently to unservice to
3. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been
in addition, in the case and the same and the same and the same are additional copies is identical to that in
my 1 Completed the required statements that the information ill life subsculptil of additional copies is required
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
my 1 Completed the required statements that the information ill life subsculptil of additional copies is required
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
filed or furnished, the required statements that the information in the subsequent of administration as filed or does not go beyond the application as filed, as appropriate, were furnished.  4. Additional comments:
filed or furnished, the required statements that the information in the subsequent of additional exploration as filed or does not go beyond the application as filed, as appropriate, were furnished.
filed or furnished, the required statements that the information in the subsequent of administration as filed or does not go beyond the application as filed, as appropriate, were furnished.  4. Additional comments:
filed or furnished, the required statements that the information in the subsequent of administration as filed or does not go beyond the application as filed, as appropriate, were furnished.  4. Additional comments:
filed or furnished, the required statements that the information in the subsequent of administration as filed or does not go beyond the application as filed, as appropriate, were furnished.  4. Additional comments:

Form PCT/ISA/237(Box No. I) (January 2004)

International application No. PCT/US04/31365

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

_			
1.	Statement		
	Novelty (N)	Claims 6, 9-11, and 13-15	YES
		Claims 1-5, 7, 8, and 12	NO
	Inventive step (IS)	Claims NONE	YES
		Claims 1-15	NO
	Industrial applicability (IA)	Claims 1-15	VEC

Claims NONE

#### 2. Citations and explanations:

Claims 1-5, 7, 8, and 12 lack novelty under PCT Article 33(2) as being anticipated by Becker 4,446,028. It is submitted that Becker disclose (see col. 2 line 3 through col. 5 line 56) a method of inhibiting scale formation in a desalting or desalination system as recited in the instant claims.

Claims 1, 2, 5, 7, 8, and 12 lack novelty under PCT Article 33(2) as being anticipated by Becker 4,446,026. It is submitted that Becker disclose (see col. 2 line 3 through col. 5 line 13) a method of inhibiting scale formation in a desalting or desalination system as recited in the instant claims.

Claims 6, 11, and 13-15 lack an inventive step under PCT Article 33(3) as being obvious over Becker (028) or Becker (026) in view of Hodgson et al. 4,204,953. The claims differ from the references as applied above by reciting the addition of a polymaleic acid or anhydride, and the inhibition of magnesium hydroxide scale. Hodgson et al. disclose (see col. 1 line 14 through col. 4 line 56) that it is known in the art to add polymaleic anhydrides to saline water evaporators to inhibit scale deposition including magnesium hydroxide. It would have been obvious to one skilled in the art to modify the references as applied above, by addition of polymaleic anhydride in view of the teachings of Hodgson et al., to aid in inhibiting scale deposition including magnesium hydroxide in the desalination system.

Claims 9 and 10 lack an inventive step under PCT Article 33(3) as being obvious over Becker (028) or Becker (026) in view of Bendiksen et al. 5,087,376. The claims differ from the references as applied above by reciting that the phosphonate polymer is poly(vinylphosphonic acid). Bendiksen et al. disclose (see col. 3 line 13 through col. 4 line 43) that it is known in the art to add a polymer of vinyl phosphonic acid to inhibit scale deposition including magnesium salts in aqueous desalination systems. It would have been obvious to one skilled in the art to modify the references as applied above, by addition of poly(vinylphosphonic acid) in view of the teachings of Bendiksen et al., to aid in inhibiting scale deposition in the desalination system.

Claims 6, 9-11, and 13-15 meet the criteria set out in PCT Article 33(2), because the prior art does not disclose a method of inhibiting scale formation comprising the method steps recited in the instant claims.

Claims 1-15 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry to inhibit scale formation in desalination systems.

Form PCT/ISA/237 (Box No. V) (January 2004)

International application No.

PCT/US04/31365

Box No. V	/II	Certain	defects in	the international	application
-----------	-----	---------	------------	-------------------	-------------

The following defects in the form or contents of the international application have been noted:

The description is objected to as containing the following defect(s) under PCT Rule 66.2(a)(iii) in the form or contents thereof: In the description on page 6 last line, "100,00" is erroneous.

Form PCT/ISA/237 (Box No. VII) (January 2004)

International application No.

PCT/US04/31365

Box No.	VШ	Certain	observations	on the	international	application
---------	----	---------	--------------	--------	---------------	-------------

The following observations on the clarity of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

Claim 9 is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claim is indefinite for the following reason(s): In claim 9 line 1 "8" appears to be erroneous, and should be changed to - 7 -. It is further noted that poly(vinylphosphonic acid) as recited in claim 9 does not appear to be included in the structure recited in claim 7.

Form PCT/ISA/237 (Box No. VIII) (January 2004)